| Non-Alcoholic Fatty Liver Disease |
1 |
1 |
| Biliary Disease |
0 |
0.97 |
| Metabolic Syndrome |
0 |
0.96 |
| Hepatic Fibrosis |
0 |
0.83 |
| Liver |
0 |
0.81 |
| Fatty Liver |
0 |
0.67 |
| Liver Disease |
0 |
0.67 |
| Lipids Management |
0 |
0.6 |
| Cardiovascular Risk Management |
0 |
0.46 |
| LDL Cholesterol |
0 |
0.3 |
| Lipoproteins |
0 |
0.22 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.21 |
| Clinical Research |
0 |
0.15 |
| Metabolism |
0 |
0.15 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Apolipoproteins |
0 |
0.07 |
| Biomarker |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Cirrhosis |
0 |
0.07 |
| Diarrhea |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Nausea |
0 |
0.07 |
| Nonalcoholic Steatohepatitis |
0 |
0.99 |
| Peer Review |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Steatosis |
0 |
0.07 |
| Texas |
0 |
0.07 |
| Thyroid |
0 |
0.07 |
| Thyroid Disease |
0 |
0.07 |
| Triglycerides |
0 |
0.07 |
| Type 2 Diabetes Mellitus |
0 |
0.07 |